AVR 0.42% $12.05 anteris technologies ltd

AHZ at biotech showcase, page-32

  1. 426 Posts.
    Kerim, you say "Admedus is no longer a speculative stock, they have actual real products."

    Firstly they have two clinical trials in progress (HSV and HPV) with the final results unknown, in other words people "speculate" on the outcome.

    Secondly the company is applying its ADAPT technologies to other areas with investors "speculating" on the overall clinical outcomes and sales potential.

    Thirdly the company is loss making and investors are "speculating" that in the future the company will turn a profit.

    A non-speculative stock doesn't trade at 12 cents.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.